PURPOSE: The purpose of this study was to report a case of a 7-year-old girl with unilateral, multifocal Reese Ellsworth Stage Vb retinoblastoma who was successfully treated using intraarterial chemotherapy infusion as the primary therapy. METHODS: This is an interventional case report. A 7-year-old girl presented with advanced unilateral retinoblastoma. The patient received intraarterial melphalan infusion therapy as the primary treatment. RESULTS: Complete tumor resolution was seen at 1 month after intraarterial melphalan infusion. CONCLUSION: This case of advanced retinoblastoma in a 7-year-old girl was successfully treated with intraarterial melphalan infusion alone. Treatment resulted in complete resolution of the tumor 1 month after treatment. In comparison with systemic chemotherapy, intraarterial melphalan infusion therapy may be a less toxic and more effective primary treatment option in the future management of advanced retinoblastoma.
PURPOSE: The purpose of this study was to report a case of a 7-year-old girl with unilateral, multifocal Reese Ellsworth Stage Vb retinoblastoma who was successfully treated using intraarterial chemotherapy infusion as the primary therapy. METHODS: This is an interventional case report. A 7-year-old girl presented with advanced unilateral retinoblastoma. The patient received intraarterial melphalan infusion therapy as the primary treatment. RESULTS: Complete tumor resolution was seen at 1 month after intraarterial melphalan infusion. CONCLUSION: This case of advanced retinoblastoma in a 7-year-old girl was successfully treated with intraarterial melphalan infusion alone. Treatment resulted in complete resolution of the tumor 1 month after treatment. In comparison with systemic chemotherapy, intraarterial melphalan infusion therapy may be a less toxic and more effective primary treatment option in the future management of advanced retinoblastoma.
Authors: Shailendra Joshi; Johann R N Cooke; Jason A Ellis; Charles W Emala; Jeffrey N Bruce Journal: J Neurooncol Date: 2017-09-05 Impact factor: 4.130
Authors: Lejla Mutapcic Vajzovic; Timothy G Murray; Mohammad A Aziz-Sultan; Amy C Schefler; Stacey Quintero Wolfe; Ditte Hess; Cristina E Fernandes; Sander R Dubovy Journal: Clin Ophthalmol Date: 2011-02-10